Research Article Details
| Article ID: | A44001 |
| PMID: | 30174510 |
| Source: | Saudi J Biol Sci |
| Title: | Effects of a medicinal plant Macrotyloma uniflorum (Lam.) Verdc.formulation (MUF) on obesity-associated oxidative stress-induced liver injury. |
| Abstract: | Obesity is a global health burden due to lifestyle modifications that have a strong association with a high incidence of diseases, such as dyslipidemia, glucose intolerance, nonalcoholic fatty liver diseases, diabetes, hypertension, coronary heart disease and cancer. The aim of the present study is to investigate the protective effects of a Macrotyloma uniflurom formulation (MUF) against high-fat diet (HFD)-induced oxidative stress and inflammation in obese rats. Male albino Wistar rats were fed a high-fat diet for 6 weeks to facilitate fat-induced oxidative stress and were simultaneously treated with MUF (400 mg/kg b.w.) through oral gavage from the third week onwards during the treatment phase. At the end of the experimental period, hepatic and oxidative stress markers were examined. The mRNA expression levels of inflammatory marker genes [Tumor Necrosis Factor-α (TNF-α) and Interleukin-6 (IL-6)] were also determined by reverse transcriptase-polymerase chain reaction in liver tissue. Hepatic marker enzymes (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and gamma glutamyl transferase) and lipid peroxidation markers (Thiobarbituric acid reactive substances and LOOH) were significantly increased in HFD-fed rats, and administration of MUF resulted in remarkable suppression of these markers. Administration of MUF to HFD rats enhanced the activity of enzymatic (superoxide dismutase, catalase and glutathione peroxidase and non-enzymatic (vitamin E, vitamin C and glutathione) antioxidants compared to HFD-fed rats. An anti-inflammatory effect of MUF was demonstrated by attenuating gene expression of TNF-α and IL-6. Therefore, the results of this study indicate that MUF could be a strong herbal therapeutic alternative for the protection of the liver as well as prevention and treatment of high-fat-induced oxidative stress and inflammation. |
| DOI: | 10.1016/j.sjbs.2018.03.010 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D386 | Vitamin C | Supplement | DB00126 | PLOD2 cofactor; PLOD3 cofactor; DBH cofactor; P3H1 cofactor; P3H2 cofactor; P3H3 cofactor; PLOD1 cofactor | -- | Under clinical trials | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D388 | Vitamin E | Supplement | DB00163 | NR1I2; ALOX5; DGKA | Anti-inflammatory | Under clinical trials | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D158 | Glutathione | Chemical drug | DB00143 | MGST3; HPGDS; GSTM2; GSTM5; GPX7 cofactor; MGST2; GSS; GSTM1; GSTK1; GSTM3; GSTM4; GPX1 cofactor; GPX2 cofactor; GPX3 cofactor | -- | Under clinical trials | Details |